- Published on
Emergency and Acute Medicine – Thrombotic Thrombocytopenic Purpura
Thrombotic thrombocytopenic purpura is a life-threatening hematologic emergency characterized by widespread microvascular thrombosis leading to multiorgan ischemia. It is classically described by a pentad consisting of thrombocytopenia, microangiopathic hemolytic anemia, neurologic abnormalities, renal dysfunction, and fever, although most patients do not present with all five features. The most consistent findings are thrombocytopenia and hemolytic anemia, and the presence of these two findings alone is sufficient to strongly suspect the diagnosis and initiate treatment.
The underlying pathophysiology involves a deficiency of the enzyme ADAMTS13, which normally cleaves large multimers of von Willebrand factor. Without this enzyme, unusually large vWF multimers promote platelet aggregation and formation of microthrombi within small vessels. These thrombi consume platelets and mechanically shear red blood cells, resulting in hemolysis. The widespread microvascular occlusion leads to ischemia in multiple organs, particularly the brain, kidneys, and heart.
TTP can occur in several forms, including idiopathic, hereditary, drug-induced, pregnancy-associated, or secondary to infections or malignancy. It most commonly affects adults between the third and sixth decades of life and is more frequent in women. Without treatment, mortality exceeds 90%, but with modern therapy, survival rates exceed 90%, making early recognition and intervention critical.
Patients often present with nonspecific symptoms such as fatigue, weakness, and fever, along with signs of bleeding like petechiae, purpura, or mucosal hemorrhage. Neurologic manifestations are common and may include confusion, headache, seizures, or focal deficits, often fluctuating in severity. Renal involvement is usually mild compared to hemolytic uremic syndrome but may include hematuria and elevated creatinine.
Diagnosis is primarily clinical and should not be delayed while awaiting confirmatory tests. Laboratory findings typically show anemia with elevated reticulocyte count, severe thrombocytopenia, elevated lactate dehydrogenase due to hemolysis and tissue ischemia, and increased indirect bilirubin. Peripheral blood smear demonstrates schistocytes, which are fragmented red blood cells. Coagulation studies are usually normal, helping to distinguish TTP from disseminated intravascular coagulation. ADAMTS13 testing may support the diagnosis but is not required to initiate treatment.
Management is a medical emergency and begins with stabilization of airway, breathing, and circulation. The cornerstone of treatment is urgent plasma exchange therapy, which removes circulating autoantibodies and replenishes functional ADAMTS13. Plasma exchange is performed daily until platelet counts normalize and clinical improvement is observed. Fresh frozen plasma may be used as a temporary measure if exchange is not immediately available.
Supportive care includes red blood cell transfusion for significant anemia, while platelet transfusion is generally avoided unless there is life-threatening bleeding, as it may worsen thrombosis. Corticosteroids are often used to reduce immune-mediated damage, and additional therapies such as rituximab may be considered in refractory or relapsing cases. Dialysis may be required in cases of significant renal failure.
Patients require hospital admission, often to an intensive care setting, particularly if neurologic symptoms or bleeding are present. Early diagnosis and prompt initiation of plasma exchange are the most important factors in improving survival. A key clinical principle is that treatment should begin as soon as TTP is suspected, even before confirmatory testing, due to the rapid progression and high mortality of untreated disease.
Thrombotic thrombocytopenic purpura is a life-threatening hematologic emergency characterized by widespread microvascular thrombosis leading to multiorgan ischemia. It is classically described by a pentad consisting of thrombocytopenia, microangiopathic hemolytic anemia, neurologic abnormalities, renal dysfunction, and fever, although most patients do not present with all five features. The most consistent findings are thrombocytopenia and hemolytic anemia, and the presence of these two findings alone is sufficient to strongly suspect the diagnosis and initiate treatment.
The underlying pathophysiology involves a deficiency of the enzyme ADAMTS13, which normally cleaves large multimers of von Willebrand factor. Without this enzyme, unusually large vWF multimers promote platelet aggregation and formation of microthrombi within small vessels. These thrombi consume platelets and mechanically shear red blood cells, resulting in hemolysis. The widespread microvascular occlusion leads to ischemia in multiple organs, particularly the brain, kidneys, and heart.
TTP can occur in several forms, including idiopathic, hereditary, drug-induced, pregnancy-associated, or secondary to infections or malignancy. It most commonly affects adults between the third and sixth decades of life and is more frequent in women. Without treatment, mortality exceeds 90%, but with modern therapy, survival rates exceed 90%, making early recognition and intervention critical.
Patients often present with nonspecific symptoms such as fatigue, weakness, and fever, along with signs of bleeding like petechiae, purpura, or mucosal hemorrhage. Neurologic manifestations are common and may include confusion, headache, seizures, or focal deficits, often fluctuating in severity. Renal involvement is usually mild compared to hemolytic uremic syndrome but may include hematuria and elevated creatinine.
Diagnosis is primarily clinical and should not be delayed while awaiting confirmatory tests. Laboratory findings typically show anemia with elevated reticulocyte count, severe thrombocytopenia, elevated lactate dehydrogenase due to hemolysis and tissue ischemia, and increased indirect bilirubin. Peripheral blood smear demonstrates schistocytes, which are fragmented red blood cells. Coagulation studies are usually normal, helping to distinguish TTP from disseminated intravascular coagulation. ADAMTS13 testing may support the diagnosis but is not required to initiate treatment.
Management is a medical emergency and begins with stabilization of airway, breathing, and circulation. The cornerstone of treatment is urgent plasma exchange therapy, which removes circulating autoantibodies and replenishes functional ADAMTS13. Plasma exchange is performed daily until platelet counts normalize and clinical improvement is observed. Fresh frozen plasma may be used as a temporary measure if exchange is not immediately available.
Supportive care includes red blood cell transfusion for significant anemia, while platelet transfusion is generally avoided unless there is life-threatening bleeding, as it may worsen thrombosis. Corticosteroids are often used to reduce immune-mediated damage, and additional therapies such as rituximab may be considered in refractory or relapsing cases. Dialysis may be required in cases of significant renal failure.
Patients require hospital admission, often to an intensive care setting, particularly if neurologic symptoms or bleeding are present. Early diagnosis and prompt initiation of plasma exchange are the most important factors in improving survival. A key clinical principle is that treatment should begin as soon as TTP is suspected, even before confirmatory testing, due to the rapid progression and high mortality of untreated disease.
0 Comments
